IntraBio Inc. today announced positive topline results from its pivotal Phase III IB1001-303 clinical trial, "Effects of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T): A Randomized, ...

If approved, levacetylleucine could become the first therapy on the market for ataxia-telangiectasia.

Phase III trial successfully achieved its primary endpoint and key secondary endpoints with high statistical significance Levacetylleucine demonstrated clinically meaningful improvements in ...

As IntraBio works to grow the global treatment market for Aqneursa in Niemann-Pick disease type C, the company is already ...

IntraBio Inc. today announced that the European Commission granted marketing authorization to AQNEURSA® (levacetylleucine) for the treatment of neurological manifestations of Niemann-Pick Type C (NPC) ...

A long-running debate over Tamiflu’s safety in children may finally be settled. Researchers found that influenza, not the antiviral medication, was linked to serious neuropsychiatric events like ...

Your doctor may give you a prescription, but it comes with a warning ...

IntraBio Inc. today announced that the European Commission granted marketing authorization to AQNEURSA(levacetylleucine) for the treatment of neurological manifestations of Niemann-Pick Type C (NPC) ...

There was an almost four-fold increase in the number of people being treated for the addictive use of volatile inhalants such as aerosols and nitrous oxide in a three-year period, an Oireachtas ...

The NHS has important information for anyone who has been prescribed clonazepam - a common medication used to treat a variety of conditions ...

In a major boost for health research, 22 UQ researchers and teams have secured $29 million from the National Health and ...

Biogen Inc. ( BIIB) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 4:30 PM EST ...